Tourmaline BioNASDAQ: TRML

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 May 2021

Next earnings report:

30 August 2024

Last dividends:

N/A

Next dividends:

N/A
$331.35 M
-71%vs. 3y high
61%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 7 min ago
$12.92+$0.20(+1.57%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TRML Latest News

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
globenewswire.com27 June 2024 Sentiment: -

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Mr. Robinson most recently held the role of Vice President, Finance and Controller at Tourmaline, in addition to serving as Tourmaline's Interim Chief Financial Officer and Treasurer since October 2023.

Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Zacks Investment Research15 March 2024 Sentiment: POSITIVE

Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6
Seeking Alpha01 November 2023 Sentiment: POSITIVE

Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. The ongoing phase 2b spiriTED study, which is using TOUR006 for the treatment of patients with active TED, is expected to release results in the first half of 2025. A phase 2 study, using TOUR006 for the treatment of patients with atherosclerotic cardiovascular disease, is expected to begin in 2024.

What type of business is Tourmaline Bio?

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

What sector is Tourmaline Bio in?

Tourmaline Bio is in the Healthcare sector

What industry is Tourmaline Bio in?

Tourmaline Bio is in the Biotechnology industry

What country is Tourmaline Bio from?

Tourmaline Bio is headquartered in United States

When did Tourmaline Bio go public?

Tourmaline Bio initial public offering (IPO) was on 07 May 2021

What is Tourmaline Bio website?

https://www.tourmalinebio.com

Is Tourmaline Bio in the S&P 500?

No, Tourmaline Bio is not included in the S&P 500 index

Is Tourmaline Bio in the NASDAQ 100?

No, Tourmaline Bio is not included in the NASDAQ 100 index

Is Tourmaline Bio in the Dow Jones?

No, Tourmaline Bio is not included in the Dow Jones index

When does Tourmaline Bio report earnings?

The next expected earnings date for Tourmaline Bio is 30 August 2024